Relapsed Follicular Lymphoma Recruiting Phase 1 / 2 Trials for Ibrutinib (DB09053)

IndicationStatusPhase
DBCOND0041364 (Relapsed Follicular Lymphoma)Recruiting1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02956382Ibrutinib and Venetoclax in Relapsed and Refractory Follicular LymphomaTreatment